Tag: Braxia Scientific - Page 2 - Psychedelic Alpha

Read more about the article Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

Post published:July 27, 2022
Post category:Press Release

Read more about the article Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

Post published:June 24, 2022
Post category:Press Release

Read more about the article Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin

Post published:December 14, 2021
Post category:Press Release

Braxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial

Post published:November 2, 2021
Post category:Press Release

Read more about the article Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading Novel Psychedelic Research and Treatments for Mental Disorders

Post published:May 5, 2021
Post category:Press Release

Read more about the article Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Post published:May 3, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.